Abbott Laboratories (ABT) Files Form 4 Insider Selling : Hubert L Allen Sells 3,400 Shares

Abbott Laboratories (ABT): Hubert L Allen , Executive Vice President of Abbott Laboratories sold 3,400 shares on Jun 28, 2016. The Insider selling transaction was reported by the company on Jun 30, 2016 to the Securities and Exchange Commission. The shares were sold at $37.14 per share for a total value of $126,276.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 17, 2016, Jared Watkin (Senior Vice President) sold 552 shares at $37.63 per share price.On Jun 3, 2016, Brian B Yoor (Senior Vice President and CFO) sold 565 shares at $39.49 per share price.Also, On Apr 29, 2016, Deepak S. Nath (Senior Vice President) sold 53 shares at $41.31 per share price.On Mar 2, 2016, Robert B Ford (Executive Vice President) sold 1,706 shares at $39.28 per share price.

Abbott Laboratories: On Wednesday, Jun 29, 2016 heightened volatility was witnessed in Abbott Laboratories which led to swings in the share price. The shares opened for trading at $37.95 and hit $38.75 on the upside , eventually ending the session at $38.57, with a gain of 2.69% or 1.01 points. The heightened volatility saw the trading volume jump to 83,66,480 shares. The 52-week high of the share price is $51.74 and the company has a market cap of $56,665 M . The 52-week low of the share price is at $36.

Abbott Laboratories Money Flow Index Chart

On Jun 10, 2016, Abbott Laboratories announced a cash dividend of $0.2600. The company’s management has announced Jul 13, 2016 as the ex-dividend date and fixed the record date on Jul 15, 2016. The payable date has been fixed on Aug 15, 2016.

Company has been under the radar of several Street Analysts.Abbott Laboratories is Upgraded by Edward Jones to Buy. Earlier the firm had a rating of Hold on the company shares. The Rating was issued on Jun 21, 2016.Abbott Laboratories is Reiterated by RBC Capital Mkts to Outperform and the brokerage firm has raised the Price Target to $ 48 from a previous price target of $45 .The Rating was issued on Apr 11, 2016.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Leave a Reply

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.